A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 21 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 18 Feb 2019.